Cargando…

Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul

OBJECTIVES: Recent studies have revealed an association between dipeptidyl peptidase 4 inhibitors (DPP4i) and development of bullous pemphigoid (BP). The main aim of our study is to evaluate the association between DPP4i treatment and BP development. The secondary endpoints were to evaluate clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ugurer, Ece, Ozkur, Ezgi, Altunay, Ilknur Kivanc, Sen, Esra Cil, Aksu, Ayse Esra Koku, Ozcan, Ilknur, Altuntas, Yuksel, Gurel, Mehmet Salih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Med Bull Sisli Etfal Hosp 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580981/ https://www.ncbi.nlm.nih.gov/pubmed/36304224 http://dx.doi.org/10.14744/SEMB.2022.30111

Ejemplares similares

Dyslipidemia in Lichen Planus: A Case-control Study
por: Özkur, Ezgi, et al.
Publicado: (2020)

More than a skin disease: stress, depression, anxiety levels, and serum neurotrophins in lichen simplex chronicus()()
por: Altunay, İlknur Kıvanç, et al.
Publicado: (2021)

The Effects of Methotrexate and Biologics on the Symptoms of Depression and Anxiety in Patients with Psoriasis
por: Uğurer, Ece, et al.
Publicado: (2023)

Comparison of topical clobetasol propionate 0.05% and topical tacrolimus 0.1% in the treatment of cutaneous lichen planus
por: Özkur, Ezgi, et al.
Publicado: (2020)

Evaluation of Comorbidities in Patients with Autoimmune Bullous Diseases: A Retrospective Study
por: Karabay, Ezgi Aktaş, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Primary scrotal melanoma: it is time to destigmatize genital lesions()()
por: Özkur, Ezgi, et al.
Publicado: (2019)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
por: Murakami, Takaaki, et al.
Publicado: (2019)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid()()
por: Gravani, Agoritsa, et al.
Publicado: (2021)

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor – A case report
por: Karthik, S, et al.
Publicado: (2019)

Evaluation of Healthy Lifestyle Behaviors in Psoriasis Patients
por: Deniz, Fatma, et al.
Publicado: (2021)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors: A report of five cases
por: Yoshiji, Satoshi, et al.
Publicado: (2017)

The Association between Melatonin Levels and Sleep Quality in Patients with Pruritus: A Potential Biomarker on a Candidate Future Treatment
por: Erdem, Yasemin, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
por: Pasmatzi, Efi, et al.
Publicado: (2011)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
por: Kinyó, Ágnes, et al.
Publicado: (2021)

Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study()()
por: Özkur, Ezgi, et al.
Publicado: (2020)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
por: Lambadiari, Vaia, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis
por: Hung, Chih-Tsung, et al.
Publicado: (2022)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
por: Balighi, Kamran, et al.
Publicado: (2022)

Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
por: Nozawa, Keisuke, et al.
Publicado: (2023)

Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
por: Kawaguchi, Yohei, et al.
Publicado: (2018)

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication
por: Shinohara, Yasutake, et al.
Publicado: (2020)

Evaluation of Dermatology Consultations in a Tertiary Care Centre Emergency Service
por: Ozkur, Ezgi, et al.
Publicado: (2020)

The Etiological Evaluation of Patients with Chronic Urticaria
por: Erdem, Yasemin, et al.
Publicado: (2020)

Lupus Miliaris Disseminatus Faciei: A Case Report and Brief Literature Review
por: Çerman, Aslı Aksu, et al.
Publicado: (2018)

The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio
por: Aktaş Karabay, Ezgi, et al.
Publicado: (2019)

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
por: Mai, Yosuke, et al.
Publicado: (2019)

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
por: Bukvić Mokos, Zrinka, et al.
Publicado: (2020)

Vitamin D levels in actinic keratosis: a preliminary study
por: Çerman, Aslı Aksu, et al.
Publicado: (2018)

Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Iwamoto, Yuichiro, et al.
Publicado: (2022)

SARS‐CoV‐2 vaccine‐triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors‐associated bullous pemphigoid
por: Nakahara, Yukiko, et al.
Publicado: (2022)

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
por: Mai, Yosuke, et al.
Publicado: (2018)

Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
por: Harada, Masaru, et al.
Publicado: (2017)

Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
por: Kridin, Khalaf, et al.
Publicado: (2022)

Detection of Squamous Cell Carcinoma Foci in a Patient with Dystrophic Epidermolysis Bullosa in (18)F-FDG PET/CT
por: Arslan, Esra, et al.
Publicado: (2019)

Pemphigoid Nodularis Induced by Long-Term Use of Dipeptidyl Peptidase-4 Inhibitors
por: Norikawa, Natsumi, et al.
Publicado: (2023)

Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor–induced bullous pemphigoid
por: Yamashita, Chigusa, et al.
Publicado: (2021)

Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ca1bl1tncpuhvl27ii3t1s45qk